CN105636593A - 包含21-o-当归酰基茶皂醇e3的生发或育发促进用组合物 - Google Patents
包含21-o-当归酰基茶皂醇e3的生发或育发促进用组合物 Download PDFInfo
- Publication number
- CN105636593A CN105636593A CN201480055367.1A CN201480055367A CN105636593A CN 105636593 A CN105636593 A CN 105636593A CN 201480055367 A CN201480055367 A CN 201480055367A CN 105636593 A CN105636593 A CN 105636593A
- Authority
- CN
- China
- Prior art keywords
- composition
- theasapogenol
- hair
- promoting
- hair growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000003779 hair growth Effects 0.000 title claims abstract description 50
- 210000004209 hair Anatomy 0.000 title abstract description 35
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 19
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 229930192129 Theasapogenol Natural products 0.000 claims description 107
- 230000001737 promoting effect Effects 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 40
- 241001597008 Nomeidae Species 0.000 claims description 32
- 244000269722 Thea sinensis Species 0.000 claims description 31
- 235000009569 green tea Nutrition 0.000 claims description 29
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 27
- 229930182490 saponin Natural products 0.000 claims description 27
- 150000007949 saponins Chemical class 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 239000004615 ingredient Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 5
- 229960002986 dinoprostone Drugs 0.000 claims description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 abstract description 7
- 230000003698 anagen phase Effects 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
- 230000003797 telogen phase Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000002552 dosage form Substances 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 201000004384 Alopecia Diseases 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- -1 antibacterial Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 231100000360 alopecia Toxicity 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000003778 catagen phase Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 241000235575 Mortierella Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 108010030923 hesperidinase Proteins 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 108010001078 naringinase Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical class NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- OLIWNBJEQIKYPQ-UHFFFAOYSA-N 3-methylheptane;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCC(C)CC OLIWNBJEQIKYPQ-UHFFFAOYSA-N 0.000 description 1
- LAIUFBWHERIJIH-UHFFFAOYSA-N 3MC7 Natural products CCCCC(C)CC LAIUFBWHERIJIH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 1
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 101000672034 Bacillus sp. (strain GL1) Unsaturated glucuronyl hydrolase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000008104 Prunus humilis Nutrition 0.000 description 1
- 241000057271 Prunus humilis Species 0.000 description 1
- 235000005706 Prunus prostrata Nutrition 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000228341 Talaromyces Species 0.000 description 1
- 241001125843 Trichiuridae Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002203 tilactase Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- OWGHQYPQNSZTFQ-UHFFFAOYSA-M triethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](CC)(CC)CC OWGHQYPQNSZTFQ-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一方面,本发明的涉及包含21-O-当归酰基茶皂醇E3作为有效成分的生发或育发促进用组合物。另一方面,本发明涉及包含21-O-当归酰基茶皂醇E3的组合物,其特征在于,通过促进毛乳头细胞增殖及人体毛囊器官中的毛发生长,缩短生长周期中从休止期过渡到生长期的周期。根据这样的本发明的一方面的组合物由于使用植物性天然物质,因此安全性优异,能够用作皮肤外用药,能够作为化妆品、药物或食品组合物广泛使用。
Description
技术领域
一方面,本发明涉及生发或育发促进用组合物,另一方面,涉及通过包含21-O-当归酰基茶皂醇(21-O-angeloyltheasapogenol)E3,缩短毛发的周期中从休止期过渡到生长期的周期,从而促进毛发生长的生发或育发促进用组合物。
背景技术
关于脱发原因,提出了雄激素作用过度理论、皮脂分泌过剩理论、血液循环不良理论、由过氧化物、细菌等导致的头皮功能降低理论、遗传因素、老化、压力等。并且,由于在社会压力的增加的同时环境污染和速食食品等西方化的饮食习惯、频繁的烫发和染色等,逐渐增加脱发人口。毛发的周期可以分为使毛发生长的生长期(anagen)、停止生长而毛球部缩小的时期即退行期(catagen)、毛乳头停止活动而使毛发停留在头皮的时期即休止期(talogen)、毛乳头开始活动或长出新毛发而脱落旧毛发的时期即发生期。
生长期(AnagenStage;2~7年)为毛发生长的期间,其再分为毛发从毛球向往毛鞘的毛发生成阶段、以及在毛囊内产生坚硬的角蛋白的阶段。毛发持续自生长直到退行期。退行期(CatagenStage;2~3周)是生长期结束、在维持毛发的形态的同时代谢过程变慢的时期,在该阶段中不产生角蛋白。退行期占整个毛发的1%。此时,毛球部发生收缩而与毛乳头分离,被毛囊包围而上升,且细胞分裂处于停止状态。休止期(TalogenStage;3个月)是毛乳头发生萎缩,毛囊逐渐收缩,毛根被往上挤而脱落。作为毛发脱落的时期,到下一个生长期步骤开始为止的寿命为3~4个月。
正常人在生长期状态的毛发多,与此相比,患有脱发(Alopecia)的人在休止期状态的毛发多而显示出可见的脱发现象。随着脱发进行,生长期的期间变短,由此毛发逐渐变少。因此,为了治疗脱发,使休止期状态的毛囊赶快过渡到生长期、且延长变短的生长期是重要的。
男性型脱发症是因所谓睾酮(Testosterone)的雄激素而出现的现象,如果该睾酮因5α-还原酶(α-reductase)而变成更强的激素即双氢睾酮(Dihydrotestosterone,DHT),则该激素作用于毛囊,将毛囊从生长期阶段诱导至退行期阶段,从而发生脱发。因此为了治疗男性型脱发症,主要使用抑制因5α-还原酶导致的DHT的生成的方法。
女性型脱发症是主要因为在闭经期之后雌激素量的减少而发生。作为用于女性型脱发的治疗药,主要使用米诺地尔或雌激素。
斑秃是因自身免疫疾病、精神压力或遗传因素而发生。这样的斑秃与雄激素性脱发的原因根本不同,治疗方法也不同,因此使用用肾上腺皮质激素药处理的方法,或者使用将米诺地尔涂布于患部或人为地诱发患部刺激的方法。
然而,在目前已知的防止脱发、促进生发以及对毛发生长具有效果的米诺地尔(minoxidil)或粘多糖生长素(trichosaccharide)等制剂的情况下,发生没有显著的功效、以及人体安全性、诱发皮肤刺激等副作用问题,因此确保安全性及功效的组合物的开发是当务之急。
发明内容
为了解决如上所述的问题,一方面,本发明发现,21-O-当归酰基茶皂醇E3具有以往未知的促进生发或育发的功效,其目的在于提供利用其的化妆品组合物、药物组合物及健康食品组合物。
一方面,本发明提供一种生发或育发促进用组合物,其含有下述化学式1所表示的茶皂醇(theasapogenol)衍生物作为有效成分。
[化学式1]
上述式中,R1和R2各自独立地为-H、C1-6烷基、-OH、-R6OH或-CHO,
R3为-H、C1-6烷基、-OH或-OOCR7,
R4为-H或-COR8,
R5为-H或C1-6烷基,
其中,R6为C1-6烷基,R7为C2-6烯基,且R8为C1-6烷基。
另一方面,本发明的提供生发或育发促进用组合物,其包含21-O-当归酰基茶皂醇(21-O-angeloyltheasapogenol)E3作为有效成分。
再另一方面,本发明提供生发或育发促进用组合物,其将来自绿茶皂苷的茶皂醇衍生物作为有效成分,一方面,其以组合物总重量为基准含有0.001至20重量%的有效成分。
再另一方面,本发明提供作为化妆品组合物、药物组合物或食品组合物的生发或育发促进用组合物。
一方面,本发明的组合物通过含有来自绿茶皂苷的21-O-当归酰基茶皂醇E3,能够显示出比以往的生发剂更优异的生发或育发促进效果。
此外,由于使用植物性天然物质,因此安全性优异,能够用作生发或育发促进用皮肤外用药,能够广泛用于化妆品组合物、药物组合物或食品组合物等。
另一方面,含有21-O-当归酰基茶皂醇E3作为有效成分的组合物具有使毛囊毛乳头细胞增殖的效果,能够显示出抑制PGE2、IL-6及IL-8生成的效果
具体实施方式
于2013年8月30日申请的韩国专利申请号10-2013-0104230为所有目的全部包含于本说明书中作为参考。此外,本申请主张全部内容作为参考包含于本说明书中的韩国专利申请号10-2013-0104230号的利益。
以下,详细说明本发明。
一方面,本发明的组合物是含有下述化学式1所表示的茶皂醇(theasapogenol)衍生物作为有效成分的生发或育发促进用组合物。
一方面,本发明涉及生发或育发促进方法,其包括:对需要促进生发或育发的个体施用下述化学式1所表示的茶皂醇(theasapogenol)衍生物。关于上述施用,可以采用本说明书中所记载的施用方法或施用量。
一方面,本发明涉及下述化学式1所表示的茶皂醇(theasapogenol)衍生物的生发或育发促进用途。
一方面,本发明涉及用于促进生发或育发的下述化学式1所表示的茶皂醇(theasapogenol)衍生物。
[化学式1]
上述式中,R1和R2各自独立地为-H、C1-6烷基、-OH、-R6OH或-CHO,
R3为-H、C1-6烷基、-OH或-OOCR7,
R4为-H或-COR8,
R5为-H或C1-6烷基,
其中,R6为C1-6烷基,R7为C2-6烯基,且R8为C1-6烷基。
另一方面,本发明的组合物为包含21-O-当归酰基茶皂醇E3的生发或育发促进用组合物。
一方面,本发明可以涉及包括对需要促进生发或育发的个体施用21-O-当归酰基茶皂醇E3的生发或育发促进方法。关于上述施用,可以采用本说明书中所记载的施用方法或施用量。
一方面,本发明可以涉及21-O-当归酰基茶皂醇E3的生发或育发促进用途。
一方面,本发明可以涉及用于促进生发或育发的21-O-当归酰基茶皂醇E3。
再另一方面,上述21-O-当归酰基茶皂醇E3可以由下述化学式2表示。即,下述化学式2相当于上述化学式1中R1为-CHO、R2为-CH3、R3为-OCOC(CH3)=CHCH3、R4为-COCH3且R5为-CH3的茶皂醇衍生物。
[化学式2]
再另一方面,上述化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3可以是来自绿茶皂苷的21-O-当归酰基茶皂醇E3。来自绿茶皂苷的21-O-当归酰基茶皂醇E3可以通过如下方法来制造,所述方法包括:利用水或有机溶剂,从绿茶种子获得含有皂苷的提取物的步骤;以及通过利用酸、碱、酶或生产上述酶的微生物,将上述提取物水解,分离21-O-当归酰基茶皂醇E3的步骤。
上述有机溶剂可以使用选自包含乙醇、甲醇、丁醇、乙醚、乙酸乙酯和氯仿的组中的一种以上的有机溶剂或它们与水的混合物,一方面,可以使用50%乙醇。上述酸可以使用选自盐酸、硫酸和硝酸中的一种以上的酸、或者上述酸与选自乙醇、甲醇和丁醇中的一种以上醇的混合溶剂。上述碱可以使用选自氢氧化钠和氢氧化钾中的一种以上的碱、或者上述碱与选自乙醇、甲醇和丁醇中的一种以上醇的混合溶剂。上述酶是将提取物中所含有的绿茶皂苷的糖键进行分解的酶,生产上述酶的微生物是生产将上述糖键进行分解的酶的微生物,由此能够去除绿茶皂苷的糖部分,生成21-O-当归酰基茶皂醇E3。此外,上述酶可以是选自葡萄糖苷酶(glucosidase)、阿拉伯糖苷酶(arabinosidase)、鼠李糖苷酶(rhamnosidase)、木糖苷酶(xylosidase)、纤维素酶(cellulase)、橙皮苷酶(hesperidinase)、柚苷酶(naringinase)、葡萄糖醛酸酶(glucuronidase)、果胶酶(pectinase)、半乳糖苷酶(galactosidase)和淀粉葡萄糖苷酶(amyloglucosidase)中的一种以上。进而,生产上述酶的微生物可以是选自曲霉(aspergillus)属、芽孢杆菌(bacillus)属、青霉(penicillium)属、根霉(rhizopus)属、根毛霉(rhizomucor)属、篮状菌(talaromyces)属、双歧杆菌(bifidobacterium)属、被孢霉(mortierella)属、隐球菌(cryptococcus)属和微杆菌(microbacterium)属中的一种以上。
如上所述,可以利用酸、碱、酶或生产上述酶的微生物进行水解后,将反应液减压浓缩而去除溶剂,向残渣加入醇并搅拌1至5次后,通过过滤去除沉淀的盐,将过滤后的滤液减压浓缩而获得粗产物,用硅胶柱色谱(氯仿:甲醇=8:1~4:1)将所获得的从粗产物分离,获得21-O-当归酰基茶皂醇E3。
一方面,本发明包括涉及来自绿茶皂苷的21-O-当归酰基茶皂醇E3的制造方法的韩国专利申请第10-2008-0088127号的全部说明书作为参考。
一方面,本说明书中所公开的组合物以组合物总重量为基准,可以包含0.001至20重量%的化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3,另一方面,可以含有0.01至15重量%、0.01至10重量%、或0.1至5重量%。一方面,本说明书中所公开的组合物中所包含的化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3以组合物总重量为基准,可以为0.001重量%以上、0.01重量%以上、0.1重量%以上、或1.0重量%以上,另一方面,可以为20重量%以下、15重量%以下、10重量%以下、或5重量%以下。当含量小于0.001重量%时,无法期待组合物的生发或育发促进效果,当超过20重量%时,在安全性或剂型制造方面存在困难,但并不特别限定于上述含量。
一方面,本说明书中所公开的组合物可以是包含化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3,具有使毛囊毛乳头细胞增殖的效果的组合物。另一方面,本说明书中所公开的组合物可以是包含化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3,使角蛋白形成细胞活化的组合物。
另一方面,本说明书中所公开的组合物可以是包含化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3,具有抑制PGE2、IL-6或IL-8的生成的效果的组合物。
一方面,本发明的生发或育发促进用组合物可以是药物组合物、化妆品组合物或健康食品组合物。
在根据本发明的一个实施例的生发或育发促进用化妆品组合物中,除了化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3之外,还可以进一步包含功能性添加物或通常的化妆品组合物中所含有的成分。上述功能性添加物可以包含选自水溶性维生素、油溶性维生素、高分子肽、高分子多糖、鞘脂和海藻提取物中的成分。
此外,在本发明的化妆品组合物中,可以与上述功能性添加物一起配合根据需要的通常的化妆品组合物中所包含的成分。作为除此之外所包含的配合成分,可以举出油脂成分、保湿剂、润肤剂、表面活性剂、有机和无机颜料、有机粉体、紫外线吸收剂、防腐剂、杀菌剂、抗氧化剂、植物提取物、pH调节剂、醇类、色素、香料、血液循环促进剂、冷感剂、止汗剂、精制水等。
根据本发明的一个实施例的生发或育发促进用化妆品组合物的剂型没有特别限定,可以根据目的而适当选择。例如,可以制成选自润肤液、柔肤水、爽肤水、紧肤水、洗剂、牛奶乳液、保湿乳液、营养乳液、按摩霜、营养霜、保湿霜、护手霜、粉底、精华液、营养精华液、面膜、香皂、洁面泡沫、洁面露、洁面霜、身体润肤露和身体洁肤露中的任一种以上的剂型,但并不限于此。
在本发明的剂型为膏、霜或凝胶的情况下,作为载体成分,可以利用动物纤维、植物纤维、蜡、石蜡、淀粉、黄蓍胶、纤维素衍生物、聚乙二醇、有机硅、膨润土、二氧化硅、滑石或氧化锌等。
在本发明的剂型为粉末或喷剂的情况下,作为载体成分,可以利用乳糖、滑石、二氧化硅、氢氧化铝、硅酸钙或聚酰胺粉末,特别是在喷剂的情况下,可以进一步包含氯氟烃、丙烷/丁烷或二甲基醚之类的推进剂。
在本发明的剂型为溶液或乳化液的情况下,作为载体成分,可以利用溶剂、溶剂化剂或乳化剂,例如有水、乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苄醇、苯甲酸苄酯、丙二醇、1,3-丁二醇油、甘油脂肪族酯、聚乙二醇或失水山梨醇的脂肪酸酯。
在本发明的剂型为悬浮液的情况下,作为载体成分,可以利用如水、乙醇或丙二醇之类的液状稀释剂、如乙氧基化异硬脂醇、聚氧乙烯山梨醇酯和聚氧乙烯失水山梨醇酯之类的悬浮剂、微晶纤维素、偏氢氧化铝、膨润土、琼脂或黄蓍胶等。
在本发明的剂型为含有表面活性剂的清洁剂的情况下,作为载体成分,可以利用脂肪族醇硫酸盐、脂肪族醇醚硫酸盐、磺基琥珀酸单酯、羟乙基磺酸盐、咪唑啉衍生物、甲基牛磺酸盐、肌氨酸盐、脂肪酸酰胺醚硫酸盐、烷基酰胺甜菜碱、脂肪族醇、脂肪酸甘油酯、脂肪酸二乙醇酰胺、植物油、羊毛脂衍生物或乙氧基化甘油脂肪酸酯等。
化妆品组合物中所包含的有效成分即化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3的含量没有特别限制,但以组合物总重量为基准,可以为0.001至20重量%,另一方面,可以为0.01至15重量%、0.01至10重量%、或0.1至5重量%。在上述有效成分满足上述含量的情况下,可以无副作用地显示出优异的功效。
根据本发明的一个实施例的生发或育发促进用药物组合物,除了化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3之外,还可以进一步含有防腐剂、稳定剂、可湿性粉剂或乳化促进剂、用于调节渗透压的盐和/或缓冲剂等药物助剂及其它有助于治疗的物质,根据通常的方法,可以以多种口服药或非口服药形态进行剂型化。
上述口服药例如为片剂、丸剂、硬质和软质胶囊剂、液剂、悬浮剂、乳化剂、糖浆剂、粉剂、散剂、细粒剂、颗粒剂、球剂等,这些剂型除了有效成分以外还可以含有表面活性剂、稀释剂(例如,乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素和甘氨酸)、润滑剂(例如,二氧化硅、滑石、硬脂酸及其镁或钙盐、以及聚乙二醇)。此外,片剂可以含有镁铝硅酸盐、淀粉糊、明胶、黄蓍胶、甲基纤维素、羧甲基纤维素钠和聚乙烯吡咯烷酮之类的结合剂,可以根据需要含有如淀粉、琼脂、海藻酸或其钠盐之类的崩解剂、吸收剂、着色剂、香味剂和甜味剂等药物添加剂。上述片剂可以通过通常的混合、颗粒化或涂布方法来制造。
此外,作为上述非口服形态,可以为透皮施用型剂型,例如注射剂、点滴剂、软膏、洗剂、凝胶、霜、喷剂、悬浮剂、乳剂、栓剂、贴片等剂型,但并不限于此。
根据本发明的一个实施例的上述药物组合物可以通过非口服、直肠、局部、透皮、皮下等施用。根据本发明的一个实施例的药物组合物例如可以局部施用于头皮。
上述有效成分的施用量的确定在本领域技术人员的水平内,药物的1天施用量虽然根据想要施用的对象的弥漫进行程度、发病时期、年龄、健康状态、并发症等多种因素而不同,但以成人为基准时,一方面可以将1μg/kg至200mg/kg的上述组合物,另一方面可以将50μg/kg至50mg/kg的上述组合物,1天分为1至3次施用,上述施用量无论何种方法也都不能限定本发明的范围。
此外,根据本发明的一个实施例的生发或育发促进用组合物可以是皮肤外用药,上述皮肤外用药是可以包括在皮肤外部涂布的任一种药的总称,多种剂型的化妆品、医药品可以包含于此。
根据本发明的一个实施例的健康食品组合物中,上述组合物可以是液状或固体状态的剂型,可以为片剂、胶囊剂、软质胶囊剂、丸剂、颗粒剂、饮料(饮剂)、减肥棒(dietbar)、巧克力、焦糖剂型或饼干类剂型,对其剂型没有特别限定。本发明的健康食品组合物除了21-O-当归酰基茶皂醇E3有效成分以外,还可以根据需要适当含有赋形剂、糖类、香料、色素、油脂类、蛋白质等。
健康食品组合物中所包含的有效成分即化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3的含量没有特别限制,但以组合物总重量为基准,可以为0.001至20重量%,另一方面,可以为0.01至15重量%、0.01至10重量%、或0.1至5重量%。在上述有效成分满足上述含量的情况下,可以无副作用地显示出优异的功效。
通过以下的实施例,更详细说明本发明。但实施例用于例示本发明,本发明的范围并不仅限于此。
[制造例1]来自绿茶皂苷的21-O-当归酰基茶皂醇E3的制造
在绿茶种子2kg中放入己酸6升,在常温下搅拌提取并脱脂后,向脱脂后的绿茶种子1kg中放入50%乙醇4升,3次回流提取后,使其在15℃沉降1天。之后,通过滤布过滤和离心分离,将残渣与滤液分离,将分离的滤液减压浓缩,并将所得到的提取物悬浮于水后,用1升乙醚提取5次而去除色素,用1-丁醇500ml将水层提取3次。由此得到的全部1-丁醇层减压浓缩,得到1-丁醇提取物,将其溶解于少量的甲醇后,添加大量的乙酸乙酯,将所生成的沉淀物干燥,从而获得绿茶种子提取物300g。
在上述获得的绿茶种子提取物10g中,加入20倍(v/w)的1NHCl-50%甲醇溶液(v/v),在80℃水浴槽中进行8小时的加热回流,使与绿茶种子粗制皂苷结合的糖进行水解。将反应液减压浓缩而去除溶剂,向残渣中加入乙醇(200ml)并搅拌后(3次),通过过滤去除沉淀的盐,然后将过滤的滤液减压浓缩而获得粗产物后,利用硅胶柱色谱(氯仿∶甲醇=7∶1~3∶1)将获得的粗产物分离,获得21-O-当归酰基茶皂醇E30.55。利用VarianGemini2000300MHz(Varian公司),确认上述获得物是否为21-O-当归酰基茶皂醇E3,结果是,显示出本说明书参考的韩国专利申请10-2008-0088127号发明的详细说明的实验例1相同的结果。
[试验例1]毛发生长因子VEGF在毛乳头细胞中的表达评价
为了确认21-O-当归酰基茶皂醇E3使作为血管形成所需的生因子的、作为过渡到毛发生长期所需的生长因子的血管内皮细胞生长因子(Vascularendothelialgrowthfactor;VEGF)表达的程度,应用活体外(invitro)体系,使用来自绿茶皂苷的21-O-当归酰基茶皂醇E3后,评价活性。
为了上述实验,将47岁男性的毛乳头真皮细胞(DermalPapillaCell;DPC)(P.11)以4×105细胞接种(seeding)于12孔板(wellplate),并在含有10%FBS(胎牛血清,fetalbovineserum)的DMEM(达尔伯克改良伊格尔培养基,Dulbecco'smodifiedEagle'smedium)培养基中培养一晚。培养后,用20ppm的来自绿茶皂苷的21-O-当归酰基茶皂醇E3进行处理。作为阴性对照组,使用DMSO。24小时后,收集(soupcollect)用来自绿茶皂苷的21-O-当归酰基茶皂醇E3处理后的混合液,使用VEGFELISA(血管内皮细胞生长因子酶联免疫吸附试验(VascularendothelialgrowthfactorEnzyme-LinkedImmunosorbentAssay);R&Dbiosystems),确认来自绿茶皂苷的21-O-当归酰基茶皂醇E3的表达程度。并且,将其结果示于表1。
如表1所示可确认到,来自绿茶皂苷的21-O-当归酰基茶皂醇E3与对照组相比显示出大的效果差异,使毛发生长因子VEGF在毛乳头细胞中的表达增加约3倍以上。由此可知,根据本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3具有优异的毛发生成促进能力。
表1
[表1]
试样 | 培养基中的VEGF(ng/ml) |
21-O-当归酰基茶皂醇E3 | 17 |
对照组 | 5 |
[试验例2]毛囊毛乳头细胞增殖效果评价
构成毛发的角蛋白由毛根部角蛋白形成细胞(keratinocyte)生成,该角蛋白形成细胞由毛乳头细胞分化。因此,如果根据本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3促进毛乳头细胞的活性,则能够促进由其分化的角蛋白形成细胞的活性,进而能够促进毛发生成。
由此,在本实验中,如下评价来自绿茶皂苷的21-O-当归酰基茶皂醇E3的毛乳头细胞活性促进效果。
首先,本发明中,使用了人毛乳头细胞(Humandermalpapillacell,首尔大学Kwon,OhSang教授)细胞株。利用含有10%胎牛血清(FBS)的达尔伯克改良伊格尔培养基(DMEM;GibcoBRL,Gaithersburg,MD,USA),在维持5%CO2、37℃的培养箱中,将上述细胞株培养24小时后,分别用1ppm、10ppm和20ppm的来自绿茶皂苷的21-O-当归酰基茶皂醇E3进行处理。作为阴性对照组,使用了DMSO。用试验物质进行处理后,在经过24小时后,使用WST-1试剂盒(Roche),测定细胞增殖能力(%)。将其结果示于表2。
如表2所示,根据本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3在10ppm和20ppm时均显著增加两种细胞的增殖。特别是,在用20ppm的来自绿茶皂苷的21-O-当归酰基茶皂醇E3进行处理时,显示出与对照组相比约1.5倍以上高的毛乳头细胞增殖增加率。这表明,根据本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3能够促进毛乳头细胞的增殖,也能够更有效促进角蛋白形成细胞的活性和毛发生成。
表2
[表2]
试样 | hDPc增殖率(%) |
21-O-当归酰基茶皂醇E3(20ppm) | 153 |
21-O-当归酰基茶皂醇E3(10ppm) | 136 |
21-O-当归酰基茶皂醇E3(1ppm) | 109 |
对照组 | 100 |
[试验例3]利用人体毛囊器官的毛发生长促进效果评价
实施了对于本发明在实际人体毛囊器官中的毛发生长促进能力的实验。
从55岁男性的后头部头皮组织分离一个毛囊器官,在William'sE培养基(含有L-谷氨酰胺(2mM)、胰岛素(10μg/ml)、氢化可的松(40ng/ml)、抗生素(1%)、抗真菌药(1%))中进行培养,培养后第3天筛选出生长的毛囊并将其切成3mm,对于该筛选出的毛囊组织,将未进行药物处理的毛囊组织作为对照组,且分别用1ppm、3ppm和5ppm的来自绿茶皂苷的21-O-当归酰基茶皂醇E3进行处理。并且,处理8天后分别测定长度以及照相。将其结果示于表3。
其结果是,如表3所示,对于毛囊器官中毛发的长度增加而言,用5ppm的来自绿茶皂苷的21-O-当归酰基茶皂醇E3处理时与对照组相比显示出更优异的毛发生长促进效果。因此,由上述表3的结果可知,根据本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3的在毛囊中促进毛发的长度增长的效果优异。
表3
[表3]
试样 | 平均增长长度(mm) |
21-O-当归酰基茶皂醇E3(5ppm) | 2.35 |
21-O-当归酰基茶皂醇E3(3ppm) | 1.93 |
21-O-当归酰基茶皂醇E3(1ppm) | 1.62 |
对照组 | 1.56 |
[试验例4]PGE、IL-6以及IL-8生成抑制实验
将人成纤维细胞以1×105细胞的浓度接种于6孔培养板中,在37℃、5%CO2培养箱中培养24小时。用500μM的H2O2对孔进行处理而赋予24小时的刺激,然后用不同浓度的钙果提取物进行处理而进行反应48小时。反应结束后,收集培养液,进行ELISA分析。此时,使用作为抗炎剂和刺激缓和剂经常使用的物质即α-红没药醇(α-bisaborol)作为对照组。PGE2使用了AssayDesign公司的试剂盒,IL-6、IL-8使用了Endogen公司的试剂盒,根据各公司的实验手册中指定的方法进行实验。对于抑制效果,根据下述数学式1进行计算,将测定结果示于表4。
如下述表4所示可确认到,通过添加本发明的来自绿茶皂苷的21-O-当归酰基茶皂醇E3,作为炎症介质的PGE2、IL-6、IL-8的生成量显著减少,显示出高的抑制效果。
[数学式1]
抑制效果={1-(测试试样-对照组)/(H2O2-对照组)}×100
表4
[表4]
下面,对根据本发明的组合物的剂型例进行说明,但可以以其他多种剂型进行应用,这只不过想要具体进行说明,并不是想要限定本发明。
[剂型例1]洗发剂
按照下述表5中所记载的组成,利用通常的方法,制造洗发剂。
表5
[表5]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.009 --> |
月桂基硫酸钠 | 10.00 |
椰油酰胺丙基甜菜碱 | 3.00 |
羧乙烯聚合物(carboxyvinyl polymer) | 0.30 |
聚季铵盐-10 | 0.20 |
十六烷基三甲基氯化铵 | 0.10 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例2]护发素
按照下述表6中所记载的组成,利用通常的方法,制造护发素。
表6
[表6]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
鲸蜡醇 | 2.00 |
硬脂醇 | 2.50 |
山萮醇 | 0.50 |
有机硅乳液 | 0.40 |
环聚二甲基硅氧烷 | 1.00 |
双十八烷基二甲基氯化铵 | 0.10 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例3]软膏
按照下述表7中所记载的组成,利用通常的方法,制造软膏。
表7
[表7]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
甘油 | 8.00 |
丁二醇 | 4.00 |
液体石蜡 | 15.00 |
β-葡聚糖 | 7.00 |
卡波姆 | 0.10 |
辛酸/癸酸三甘油酯 | 3.00 |
角鲨烷 | 1.00 |
鲸蜡硬脂基葡糖苷 | 1.50 |
失水山梨醇硬脂酸酯 | 0.40 |
鲸蜡硬脂醇 | 1.0010 --> |
蜂蜡 | 4.00 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例4]生发油
按照下述表8中所记载的组成,利用通常的方法,制造软膏。
表8
[表8]
成分 | 含量(重量%) |
乙醇 | 55.0 |
蓖麻子油 | 5.00 |
甘油 | 3.00 |
吡罗克酮乙醇胺盐 | 0.10 |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 1.00 |
香料、色素 | 适量 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例5]头发洗剂
按照下述表9中所记载的组成,利用通常的方法,制造软膏。
表9
[表9]
成分 | 含量(重量%) |
鲸蜡硬脂醇(setostearyl alcohol) | 2.00 |
硬脂基三乙基氯化铵 | 2.00 |
羟乙基纤维素 | 0.50 |
吡罗克酮乙醇胺盐 | 0.10 |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 10.0 |
香料、色素 | 0.50 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例6]头发香皂
按照下述表10中所记载的组成,利用通常的方法,制造软膏。
表10
[表10]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 5.00 |
二氧化钛 | 0.2011 --> |
聚乙二醇 | 0.80 |
甘油 | 0.50 |
乙二胺四乙酸 | 0.05 |
钠 | 1.00 |
色素 | 适量 |
香皂香 | 适量 |
化妆皂基(水分13%,重量份) | 至100 |
合计 | 100.00 |
[剂型例7]洗剂
按照下述表11中所记载的组成,利用通常的方法,制造洗剂。
表11
[表11]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
L-抗坏血酸-2-磷酸镁盐 | 1.00 |
水溶性胶原蛋白(1%水溶液) | 1.00 |
柠檬酸钠 | 0.10 |
柠檬酸 | 0.05 |
甘草提取物 | 0.20 |
1,3-丁二醇 | 3.00 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例8]霜(cream)
按照下述表12中所记载的组成,利用通常的方法,制造霜。
表12
[表12]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
聚乙二醇单硬脂酸酯 | 2.00 |
自乳化型单硬脂酸甘油酯 | 5.00 |
鲸蜡醇 | 4.00 |
角鲨烷 | 6.00 |
三2-乙基己烷甘油(tri 2-ethyl hexane Glyceryl) | 6.00 |
鞘糖脂 | 1.00 |
1,3-丁二醇 | 7.00 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例9]面膜
按照下述表13中所记载的组成,利用通常的方法,制造面膜。
表13
[表13]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
聚乙烯醇 | 13.00 |
L-抗坏血酸-2-磷酸镁盐 | 1.00 |
月桂酰羟脯氨酸 | 1.00 |
水溶性胶原蛋白(1%水溶液) | 2.00 |
1,3-丁二醇 | 3.00 |
乙醇 | 5.00 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例10]美溶液型制剂
按照下述表14中所记载的组成,利用通常的方法,制造美溶液型制剂。
表14
[表14]
成分 | 含量(重量%) |
化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3 | 2.00 |
羟乙基纤维素(2%水溶液) | 12.00 |
黄原胶(2%水溶液) | 2.00 |
1,3-丁二醇 | 6.00 |
浓甘油 | 4.00 |
透明质酸钠(1%水溶液)5.00 | 5.00 |
精制水 | 剩余量 |
合计 | 100.00 |
[剂型例11]软质胶囊剂
将50mg化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3、L-肉碱80~140mg、大豆油180mg、棕榈油2mg、植物性硬化油8mg、黄蜡4mg以及卵磷脂6mg混合,根据通常的方法,每一个胶囊填充400mg,制造软质胶囊。
[剂型例12]片剂
将50mg的化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3、低聚半乳糖200mg、乳糖60mg以及麦芽糖140mg混合,利用流化床干燥器进行颗粒化后,添加糖酯(sugarester)6mg,用压片机进行压片,制造片剂。
[剂型例13]颗粒剂
将50mg的化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3、无水结晶葡萄糖250mg以及淀粉550mg混合,利用硫化床造粒机,成型为颗粒后,填充至袋子,制造颗粒剂。
[剂型例14]饮剂
将50mg的化学式1所表示的茶皂醇衍生物或21-O-当归酰基茶皂醇E3、葡萄糖10g、柠檬酸0.6g、以及液状低聚糖25g混合后,加入精制水300ml,向每个瓶子添加200ml。填充至瓶子后,在130℃杀菌4~5秒,制造饮剂饮料。
Claims (10)
1.一种生发或育发促进用组合物,其含有下述化学式1所表示的茶皂醇衍生物作为有效成分,
化学式1
上述式中,R1和R2各自独立地为-H、C1-6烷基、-OH、-R6OH或-CHO,R3为-H、C1-6烷基、-OH或-OOCR7,R4为-H或-COR8,R5为-H或C1-6烷基,其中,R6为C1-6烷基,R7为C2-6烯基,且R8为C1-6烷基。
2.根据权利要求1所述的生发或育发促进用组合物,其中,所述有效成分为21-O-当归酰基茶皂醇E3。
3.根据权利要求2所述的生发或育发促进用组合物,其中,所述21-O-当归酰基茶皂醇E3由下述化学式2表示,
化学式2
4.根据权利要求1所述的生发或育发促进用组合物,其中,所述有效成分来自绿茶皂苷。
5.根据权利要求1所述的生发或育发促进用组合物,其中,所述组合物以组合物总重量为基准含有0.001至20重量%的所述有效成分。
6.根据权利要求1所述的生发或育发促进用组合物,其中,所述组合物具有使毛囊毛乳头细胞增殖的效果。
7.根据权利要求1所述的生发或育发促进用组合物,其中,所述组合物具有抑制PGE2、IL-6或IL-8生成的效果。
8.根据权利要求1~7中任一项所述的生发或育发促进用组合物,其中,所述组合物为化妆品组合物。
9.根据权利要求1~7中任一项所述的生发或育发促进用组合物,其中,所述组合物为药物组合物。
10.根据权利要求1~7中任一项所述的生发或育发促进用组合物,其中,所述组合物为食品组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130104230A KR102061716B1 (ko) | 2013-08-30 | 2013-08-30 | 21-o-안젤로일티아사포제놀 e3을 포함하는 발모 또는 육모 촉진용 조성물 |
KR10-2013-0104230 | 2013-08-30 | ||
PCT/KR2014/007768 WO2015030422A1 (ko) | 2013-08-30 | 2014-08-21 | 21-o-안젤로일티아사포제놀 e3을 포함하는 발모 또는 육모 촉진용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105636593A true CN105636593A (zh) | 2016-06-01 |
CN105636593B CN105636593B (zh) | 2018-09-18 |
Family
ID=52586904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480055367.1A Active CN105636593B (zh) | 2013-08-30 | 2014-08-21 | 包含21-o-当归酰基茶皂醇e3的生发或育发促进用组合物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6386053B2 (zh) |
KR (1) | KR102061716B1 (zh) |
CN (1) | CN105636593B (zh) |
WO (1) | WO2015030422A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101957849B1 (ko) * | 2015-03-31 | 2019-03-15 | (주)아모레퍼시픽 | 발모 또는 육모 촉진용 및 항염용 조성물 |
KR102406000B1 (ko) * | 2015-09-30 | 2022-06-08 | (주)아모레퍼시픽 | 소야사포닌을 함유하는 발모 및/또는 육모 촉진용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144082A (zh) * | 1995-08-25 | 1997-03-05 | 蔡汉宏 | 茶籽洗发粉生产工艺 |
CN101336970A (zh) * | 2008-08-18 | 2009-01-07 | 盛立新 | 用于治疗和防止白发、脱发的中草药 |
KR20100029369A (ko) * | 2008-09-08 | 2010-03-17 | (주)아모레퍼시픽 | 녹차 사포닌 21-o-안젤로일티아사포제놀 e3의 제조방법 |
KR20110112019A (ko) * | 2010-04-06 | 2011-10-12 | 전도용 | 탈모 방지 및 발모 촉진용 모발 화장료 조성물 및 그 제조방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723149A (en) | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
FR2695561B1 (fr) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
US20020013294A1 (en) * | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20070129430A1 (en) * | 2003-10-07 | 2007-06-07 | Satomi Miyata | Agent for enhancing the production of collagen, their preparation and use |
US20120277308A1 (en) * | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
KR101914157B1 (ko) * | 2011-08-24 | 2018-12-31 | (주)아모레퍼시픽 | 녹차 성분을 함유하는 화장료 조성물 |
-
2013
- 2013-08-30 KR KR1020130104230A patent/KR102061716B1/ko active IP Right Grant
-
2014
- 2014-08-21 JP JP2016538842A patent/JP6386053B2/ja active Active
- 2014-08-21 WO PCT/KR2014/007768 patent/WO2015030422A1/ko active Application Filing
- 2014-08-21 CN CN201480055367.1A patent/CN105636593B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144082A (zh) * | 1995-08-25 | 1997-03-05 | 蔡汉宏 | 茶籽洗发粉生产工艺 |
CN101336970A (zh) * | 2008-08-18 | 2009-01-07 | 盛立新 | 用于治疗和防止白发、脱发的中草药 |
KR20100029369A (ko) * | 2008-09-08 | 2010-03-17 | (주)아모레퍼시픽 | 녹차 사포닌 21-o-안젤로일티아사포제놀 e3의 제조방법 |
KR20110112019A (ko) * | 2010-04-06 | 2011-10-12 | 전도용 | 탈모 방지 및 발모 촉진용 모발 화장료 조성물 및 그 제조방법 |
Non-Patent Citations (1)
Title |
---|
温柳娟等: "茶籽皂素的提取及应用研究", 《广州化工》 * |
Also Published As
Publication number | Publication date |
---|---|
JP6386053B2 (ja) | 2018-09-05 |
KR20150025984A (ko) | 2015-03-11 |
CN105636593B (zh) | 2018-09-18 |
WO2015030422A1 (ko) | 2015-03-05 |
WO2015030422A9 (ko) | 2016-03-24 |
JP2016529287A (ja) | 2016-09-23 |
KR102061716B1 (ko) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6697479B2 (ja) | 発毛又は育毛促進用及び抗炎用組成物 | |
US10967028B2 (en) | Composition for hair loss prevention or hair growth stimulation comprising Artemisia umbelliformis extract | |
KR101698922B1 (ko) | 발모 및 육모 촉진용 조성물 | |
JP4681230B2 (ja) | フィトスフィンゴシンのスリミング剤としての化粧的使用、及び、フィトスフィンゴシンを含む化粧組成物 | |
CN110325194A (zh) | 用于防止脱发及促进生发的包含水产动物发酵产物的组合物 | |
CN107635561A (zh) | 含有茶皂醇衍生物作为活性成分的组合物 | |
JP6860558B2 (ja) | ソヤサポニンを含有する発毛および/または育毛促進用組成物 | |
EP3205346B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
CN105636593B (zh) | 包含21-o-当归酰基茶皂醇e3的生发或育发促进用组合物 | |
KR101810139B1 (ko) | 발모 및 육모 촉진용 조성물 | |
KR101935492B1 (ko) | 야라야라를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR101273027B1 (ko) | 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물 | |
CN107530253B (zh) | 含有补骨脂定的用于促进生发及/或育发的组合物 | |
KR102406692B1 (ko) | 콩발아배아 추출물을 유효성분으로 포함하는 발모 촉진용 조성물 | |
JP2001354526A (ja) | 毛髪発生又は育毛剤 | |
JP6161953B2 (ja) | 育毛剤、筋肉活性化剤及びエネルギー産生促進剤 | |
JP2017088539A (ja) | セラミド産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |